Efficacy
ORAL Strategy Safety Outcomes
  • AE rates, including rates of the most common AEs, were comparable between treatment arms.1
  • The majority of AEs were mild or moderate in severity.1
Adapted from Fleischmann R et al. 2017.1

Safety analysis set was identical to the full analysis set. Two (1%) of patients receiving XELJANZ monotherapy died during the first year of therapy.1

*Patients could have experienced more than one AE.1
Explore more
Safety & Tolerability
Please click here for an overview of the safety profile of XELJANZ across all licensed indications.
VISIT PAGE
>
AE, adverse event; BID, twice-daily; MTX, methotrexate; Q2W, once every 2 weeks; SAE, serious adverse event. ​​​​​​​
References
1. Fleischmann R et al. Lancet 2017; 390:457–468.
PP-XEL-GBR-3116. August 2021
XELJANZ Risk Minimisation Programme (RMP) materials, including a Patient Alert Card, Prescriber Checklists and a Prescriber Brochure are available from https://www.medicines.org.uk/emc/. Patients treated with XELJANZ should be given the Patient Alert Card.

© 2021 Pfizer Pte Ltd. All rights reserved.


The information provided in this site is intended only for Health Care Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Corporation Singapore Limited is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.